TrialPath
Recruiting

A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosus

NCT07630714 · AstraZeneca
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Multicenter, Open-Label, Phase II Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosus
About this study
This is an open-label, multicenter study. The study includes - * Screening Period of up to 35 days * Period A (12-week, open-label treatment period) * Period B (a possible 12-week dosing regimen adjustment period, if required) * Treatment Extension Period (up-to-40-week, optional) * Period C (a 12-week safety follow-up period) The study intervention (anifrolumab) will be administered subcutaneously using an accessorized pre-filled syringe (APFS) in 2 cohorts.
Eligibility criteria
Inclusion Criteria: * Diagnosis of SLE. * Must be receiving at least one of the following SoC regimens for ≥ 4 weeks: oral glucocorticoids (≤1.0 mg/kg/day or ≤ 40 mg/day prednisone equivalent), antimalarials (hydroxychloroquine, chloroquine, or quinacrine), or a single permitted immunosuppressant (azathioprine, mycophenolate mofetil/mycophenolic acid, methotrexate, mizoribine, or tacrolimus) within specified dose limits. * Participant must have moderate to severe active SLE disease defined as Systemic lupus erythematosus disease activity index 2000 (SLEDAI-2K) ≥ 6 total points. * Body weight ≥ 15 kg. * Participants must agree to follow study specific contraception requirements as per local regulations. Exclusion Criteria: * Known diagnosis of an IFN mediated autoinflammatory interferonopathy. * History of, or current diagnosis of, clinically significant non-SLE related vasculitides. * Active, severe SLE-driven renal disease with significant proteinuria. * Active severe or unstable neuropsychiatric SLE including but not limited to aseptic meningitis; cerebral vasculitis; myelopathy; demyelination syndromes (ascending, transverse, acute inflammatory demyelinating polyradiculopathy); acute confusional state; impaired level of consciousness; psychosis; acute stroke or stroke syndrome; cranial neuropathy; status epilepticus; cerebellar ataxia; and mononeuritis multiplex. * In participants ≥ 11 years of age, a history or evidence of suicidal ideation (severity of 4 \[active: method and intent, but no plan\] or 5 \[active: method, intent, and plan\]) within the past 6 months; or any suicidal behavior within the past 12 months or recurrent suicidal behavior in the lifetime of the participant based on an assessment with the Columbia suicide severity rating scale (C-SSRS). * History of, or current diagnosis of, catastrophic antiphospholipid syndrome (APS). * History of recurrent or opportunistic infection requiring hospitalization and intravenous (IV) antibiotics. * Known history of a primary immunodeficiency, splenectomy, or any underlying condition that predisposes the participant to infection, or a positive result for human immunodeficiency virus (HIV) infection. * Active hepatitis B and C infection. * Any active or recent herpes zoster (HZ) infection that has not completely resolved within 12 weeks prior to study entry or that emerges between screening and Day 1. * Any history of severe or recurrent HZ, including non-cutaneous HZ, herpes encephalitis, ophthalmic herpes, or 2 or more prior HZ episodes. * Any cytomegalovirus (CMV) or Epstein Barr virus (EBV) infection that has not completely resolved. * History of cancer. * Prior receipt of anifrolumab. * Prior treatment with directly acting cytotoxic B-cell depleting therapeutics. * A known history of allergy or reaction to any component of the study intervention formulation or history of anaphylaxis to any human gamma globulin therapy, human proteins, or monoclonal antibodies (mAbs).
Study design
Enrollment target: 24 participants
Allocation: non_randomized
Masking: none
Age groups: child
Timeline
Starts: 2026-08-31
Estimated completion: 2031-09-05
Last updated: 2026-11-18
Interventions
Combination Product: Anifrolumab + APFS
Primary outcomes
  • • Maximum observed serum (peak) concentration (Cmax) (Cohort 1: From Day 1 to Day 8; Cohort 2: From Day 1 to Day 11)
  • • Area under the serum concentration-time curve (AUC) (Cohort 1: From Day 1 to Day 8; Cohort 2: From Day 1 to Day 11)
  • • Time to maximum plasma concentration (tmax) (Cohort 1: From Day 1 to Day 8; Cohort 2: From Day 1 to Day 11)
Sponsor
AstraZeneca · industry
Contacts & investigators
ContactAstraZeneca Clinical Study Information Center · contact · information.center@astrazeneca.com · 1-877-240-9479
All locations (39)
Research SiteNot Yet Recruiting
Nedlands, Australia
Research SiteNot Yet Recruiting
Parkville, Australia
Research SiteNot Yet Recruiting
Southport, Australia
Research SiteNot Yet Recruiting
Westmead, Australia
Research SiteNot Yet Recruiting
Brussels, Belgium
Research SiteNot Yet Recruiting
Ghent, Belgium
Research SiteNot Yet Recruiting
Leuven, Belgium
Research SiteNot Yet Recruiting
Liège, Belgium
Research SiteNot Yet Recruiting
Santiago, Chile
Research SiteNot Yet Recruiting
Santiago, Chile
Research SiteNot Yet Recruiting
Santiago, Chile
Research SiteNot Yet Recruiting
Haifa, Israel
Research SiteNot Yet Recruiting
Kfar Saba, Israel
Research SiteNot Yet Recruiting
Petah Tikva, Israel
Research SiteNot Yet Recruiting
Ramat Gan, Israel
Research SiteNot Yet Recruiting
Tel Aviv, Israel
Research SiteNot Yet Recruiting
Ginowan-shi, Japan
Research SiteNot Yet Recruiting
Kagoshima, Japan
Research SiteNot Yet Recruiting
Kanazawa, Japan
Research SiteNot Yet Recruiting
Niigata, Japan
Research SiteNot Yet Recruiting
Setagaya-ku, Japan
Research SiteNot Yet Recruiting
Amsterdam, Netherlands
Research SiteNot Yet Recruiting
Rotterdam, Netherlands
Research SiteRecruiting
Utrecht, Netherlands
Research SiteNot Yet Recruiting
Lima, Peru
Research SiteNot Yet Recruiting
Lima, Peru
Research SiteNot Yet Recruiting
Lima, Peru
Research SiteNot Yet Recruiting
Lima, Peru
Research SiteNot Yet Recruiting
Cebu City, Philippines
Research SiteNot Yet Recruiting
Dagupan, Philippines
Research SiteNot Yet Recruiting
Davao City, Philippines
Research SiteNot Yet Recruiting
Manila, Philippines
Research SiteNot Yet Recruiting
Manila, Philippines
Research SiteNot Yet Recruiting
Lisbon, Portugal
Research SiteNot Yet Recruiting
Lisbon, Portugal
Research SiteNot Yet Recruiting
Porto, Portugal
Research SiteNot Yet Recruiting
Porto, Portugal
Research SiteRecruiting
Belgrade, Serbia
Research SiteRecruiting
Niš, Serbia
A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosus · TrialPath